期刊
JOURNAL OF GENERAL VIROLOGY
卷 90, 期 -, 页码 1119-1123出版社
MICROBIOLOGY SOC
DOI: 10.1099/vir.0.009308-0
关键词
-
资金
- NIAID NIH HHS [R01 AI088744, R01 AI069275, 5R01AI06275-03] Funding Source: Medline
Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-gamma) production in the lungs of RSV-infected mice. Its F(ab')(2) component only mediates decreased leukocyte trafficking and IFN-gamma production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据